CCRM
Avinash Tripathi is an experienced professional in the biotechnology and biomedical fields, currently serving as an Operations Associate at CCRM since November 2021, where responsibilities include documentation related to change control and aseptic processing in controlled environments. Previous roles include part-time Biomedical Data Analyst at BenchSci, Production Technologist at Apotex Inc., and Laboratory Technologist at York University, contributing to various areas such as production processes, laboratory operations, and data analysis. Avinash has also held positions as a Drug Substance Production Technologist at Therapure Biopharma Inc. and as a Research Assistant at multiple institutions, including York University and the University of Manitoba, with a focus on protein interactions and phosphorylation studies. Avinash holds a Master's degree in Biology from York University and a Master's and Bachelor's degree in Biotechnology from Bangalore University.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.